Basal Cell Carcinoma Treatment Market Report 2025

This report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The basal cell carcinoma treatment market size has grown rapidly in recent years. It will grow from $7.42 billion in 2024 to $8.2 billion in 2025 at a compound annual growth rate (CAGR) of 10.6%. The growth in the historic period can be attributed to increasing prevalence of skin cancer, demand for laser therapy, demand for effective and minimally invasive treatments, rising awareness of basal cell carcinoma treatment.

The basal cell carcinoma treatment market size is expected to see strong growth in the next few years. It will grow to $11.88 billion in 2029 at a compound annual growth rate (CAGR) of 9.7%. The growth in the forecast period can be attributed to growing focus on quality of life, aging population, growing research and development in immunotherapies, government initiatives. Major trends in the forecast period include advancements in treatment modalities, early detection technologies, advancements in targeted therapies, telemedicine integration.

The increasing occurrences of skin cancer, notably basal cell carcinoma, are anticipated to drive growth in the treatment market in the future. Skin cancer is characterized by the uncontrolled growth of abnormal cells in the skin, often linked to exposure to ultraviolet (UV) radiation from the sun or tanning devices. The growing prevalence of skin cancer, particularly basal cell carcinoma, underscores the need for targeted and specialized treatment options, driving the development and availability of effective medications tailored to combat this specific cancer type. For example, in January 2023, the American Cancer Society, Inc., reported that the United States witnessed approximately 5.4 million cases of basal and squamous cell skin cancer each year, affecting around 3.3 million individuals, with basal cell carcinoma accounting for eight out of every ten cases. Consequently, the increasing incidence of skin cancer, including basal cell carcinoma, is poised to stimulate growth in the treatment market.

The global increase in the elderly population is anticipated to act as a driving force behind the growth of the basal cell carcinoma treatment market. The term 'geriatric population' pertains to individuals typically aged 65 and older, and this group is more vulnerable to basal cell carcinoma (BCC) due to prolonged sun exposure, a primary risk factor for BCC. Consequently, the aging population's heightened susceptibility contributes to a greater demand for the diagnosis and treatment of BCC. For instance, data from the United Nations Department of Economic and Social Affairs in July 2022 predicts that the percentage of the global population aged 65 and above is set to rise from 10% in 2022 to 16% by 2050. Hence, the increasing geriatric population worldwide is a key driver for the growth of the basal cell carcinoma treatment market.

Key companies in the basal cell carcinoma treatment market are focusing on advancing technologies such as lyophilization (freeze-drying) to improve the efficacy and shelf-life of topical treatments, as well as to enhance the precise delivery of active ingredients to targeted cancer cells. Lyophilization is a process where a substance is frozen and then placed under a vacuum, causing the water to sublimate and leaving the material in a stable, dry form. For example, in August 2022, Accord Healthcare, Inc., a US-based pharmaceutical company, introduced Carmustine, a generic chemotherapy drug approved by the FDA for treating certain brain tumors and blood cancers. Carmustine is used for treating various malignant brain tumors, including glioblastomas, astrocytomas, and medulloblastomas, as well as relapsed or refractory Hodgkin's lymphoma and multiple myelomas, among other blood cancers.

In July 2022, Regeneron Pharmaceuticals Inc., a US-based biopharmaceutical company, secured exclusive licensing rights to Libtayo from Sanofi SA for a sum of $900 million. This acquisition strengthens Regeneron Pharmaceuticals, Inc.'s presence in the field of oncology by granting it the rights to develop, market, and manufacture Libtayo, a prescription medication designed for the treatment of individuals with cutaneous squamous cell carcinoma (CSCC) and advanced basal cell carcinoma, two types of skin cancer. Sanofi SA, a pharmaceutical firm headquartered in France, is responsible for the development of the basal cell carcinoma treatment drug, Libtayo.

Major companies operating in the basal cell carcinoma treatment market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi SA, Fresenius Kabi AG, AstraZeneca PLC, GlaxoSmithKline PLC, Eli Lilly and Company, Gilead Sciences Inc., Merck KGaA, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Bausch Health Companies Inc., Sun Pharmaceutical Industries Ltd., Perrigo Company PLC, Incyte Corporation, Ono Pharma UK Ltd., Cipla Inc., Lupin Limited, Mallinckrodt Pharmaceuticals, LEO Pharma A/S, BeiGene Ltd., Taro Pharmaceutical Industries Ltd., Blueprint Medicines Corporation, Array BioPharma Inc., Genentech USA Inc., Palvella Therapeutics LLC.

North America was the largest region in the basal cell carcinoma treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in basal cell carcinoma treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the basal cell carcinoma treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The basal cell carcinoma treatment market consists of revenues earned by entities by providing surgical excision, Moh's surgery, cryosurgery, photodynamic therapy (PDT) and laser therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The basal cell carcinoma treatment market also includes sales of topical treatment and advanced medication. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

Basal cell carcinoma (BCC) is a form of skin cancer originating from basal cells, which are responsible for generating new skin cells. It often appears as a small, translucent lump but can have varied presentations. Effective treatment strategies for basal cell carcinoma (BCC) involve tumor removal, considering tumor characteristics, location, size, patient preferences and the practicality of follow-up appointments.

The main types of basal cell carcinoma treatment are surgery, medication and other treatments. Surgery refers to a branch of medicine that involves treating diseases and conditions through operative or manual procedures, including cutting, abrading, suturing, or otherwise physically changing body tissues and organs and surgeries are also vital for basal cell carcinoma patients, removing tumors to achieve effective treatment and minimize damage. The treatments options are administered by oral, parenteral and other routes and are distributed through hospital pharmacy, online pharmacy and retail pharmacy channels for end users such as hospitals, specialty clinics and others.

The basal cell carcinoma treatment market research report is one of a series of new reports that provides basal cell carcinoma treatment market statistics, including basal cell carcinoma treatment industry global market size, regional shares, competitors with a basal cell carcinoma treatment market share, detailed basal cell carcinoma treatment market segments, market trends and opportunities and any further data you may need to thrive in the basal cell carcinoma treatment industry. This basal cell carcinoma treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.